Analysis of Different Circulating Immune Cells in Patients With Recurrent Glioblastoma or Mixed Anaplasic Glioma Treated With Bevacizumab and Search for a Link With Response to Treatment
The following leucocyte subsets will be analyzed in whole blood before treatment and before
cycles 3, 5 and 7:
- Classical, intermediate, nonclassical and Tie2 expressing monocytes.
- Regulatory T cells (Treg).
- Myeloid Derived Suppressor cells (MDSCs) The variation of the absolute numbers (or
relative percentages) of the cells in the blood of patients will be correlated to the
response to treatment assessed according to the RANO criteria.
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
blood cells populations
Analysis of blood cells populations variation during treatment with bevacizumab. Last sampling planned before the 7th cycle of bevacizumab.
up to 4 months
Veronique QUILLIEN, MD
Center Eugene Marquis
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)